U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a new federal initiative to build a comprehensive autism data platform using Medicare and Medicaid records. Designed to study the causes of autism spectrum disorder (ASD), the platform will integrate claims data, electronic health records, and data from wearable health devices, according to the Department of Health and Human Services (HHS).
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on the effort, which is part of a broader $50 million research initiative to investigate potential environmental and medical causes of autism. Kennedy stated the project aims to provide "honest answers families have waited far too long to hear," despite his controversial history promoting a debunked link between vaccines and autism.
HHS said the platform will help researchers analyze autism diagnoses, treatment outcomes, healthcare access disparities, and the financial impact on families. However, experts like Dr. Helen Tager-Flusberg of Boston University argue the focus does not directly address autism’s root causes. She also noted that an existing NIH autism database recently went offline without explanation, raising concerns about transparency.
The project has sparked privacy questions, as HHS has not confirmed whether the database will be anonymous or voluntary. Autism researcher Eric Rubenstein noted that Medicaid and Medicare data offer insights into health disparities but lack environmental exposure data, which Kennedy claims he will explore.
Autism rates have surged in recent years, with the CDC reporting 1 in 31 U.S. 8-year-olds diagnosed in 2022. While Kennedy aims to identify autism’s causes by September, scientists emphasize that autism likely stems from a complex mix of genetic and environmental factors. Critics warn against oversimplifying this ongoing scientific challenge.


Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Faith Leaders Arrested on Capitol Hill During Protest Against Trump Immigration Policies and ICE Funding
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Trump Administration Expands Global Gag Rule, Restricting U.S. Foreign Aid to Diversity and Gender Programs
Japan Urges Fishermen to Avoid Senkaku Islands as China Tensions Rise
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Trump Orders DHS to Avoid Protests in Democratic Cities Unless Federal Assets Are Threatened
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Trump Appoints Colin McDonald as Assistant Attorney General for National Fraud Enforcement 



